Overexpression of Dyrk1A contributes to neurofibrillary degeneration in down syndrome

Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy

Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359 · see citing works

Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease

Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668 · see citing works

Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective

Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849 · see citing works

Microtubule-associated protein tau. A component of Alzheimer paired helical filaments.

Grundke, I., Iqbal, K., Quinlan, M., Tung, Y. C., Zaidi, M. S., & Wisniewski, H. M. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38495-8 · Cited by 1,780 · see citing works

The specificities of protein kinase inhibitors: an update

BAIN, J., McLAUCHLAN, H., ELLIOTT, M., & COHEN, P. (2003) · Biochemical Journal · doi:10.1042/bj20021535 · Cited by 1,369 · cited 1× · see citing works

Occurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome

Wisniewski, K. E., Wisniewski, H. M., & Wen, G. Y. (1985) · Annals of Neurology · doi:10.1002/ana.410170310 · Cited by 1,159 · see citing works

Hyperphosphorylation induces self-assembly of τ into tangles of paired helical filaments/straight filaments

Alonso, A. D. C., Zaidi, T., Novák, M., Grundke, I., & Iqbal, K. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.121119298 · Cited by 968 · see citing works

Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding

Bramblett, G. T., Goedert, M., Jakes, R., Merrick, S. E., Trojanowski, J. Q., & Lee, V. M. Y. (1993) · Neuron · doi:10.1016/0896-6273(93)90057-x · Cited by 903 · see citing works

Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation

Liu, F., Grundke‐Iqbal, I., Iqbal, K., & Gong, C. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04391.x · Cited by 759 · see citing works

Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease.

Alonso, A. C., Zaidi, T., Grundke-Iqbal, I., & Iqbal, K. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.12.5562 · Cited by 738 · see citing works

NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21

Arron, J. R., Winslow, M. M., Polleri, A., Chang, C.-P., Wu, H., Gao, X., Neilson, J. R., Chen, L., Heit, J. J., Kim, S. K., et al. (2006) · Nature · doi:10.1038/nature04678 · Cited by 698 · see citing works

DSCR1, overexpressed in Down syndrome, is an inhibitor of calcineurin-mediated signaling pathways

Fuentes, J. –. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.11.1681 · Cited by 465 · see citing works

Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis

Hanger, D. P., Byers, H. L., Wray, S., Leung, K.-Y., Saxton, M. J., Seereeram, A., Reynolds, C. H., Ward, M. A., & Anderton, B. H. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703269200 · Cited by 455 · see citing works

Phosphorylation of Microtubule-associated Protein Tau Is Regulated by Protein Phosphatase 2A in Mammalian Brain

Gong, C.-X., Lidsky, T., Wegiel, J., Zuck, L., Grundke-Iqbal, I., & Iqbal, K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5535 · Cited by 405 · see citing works

A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT

Gwack, Y., Sharma, S., Nardone, J., Tanasă, B., Iuga, A. C., Srikanth, S., Okamura, H., Bolton, D. L., Feske, S., Hogan, P. G., et al. (2006) · Nature · doi:10.1038/nature04631 · Cited by 397 · see citing works

GSK-3 is essential in the pathogenesis of Alzheimer's disease

Takashima, A. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-9s335 · Cited by 395 · see citing works

Alzheimer's neurofibrillary pathology and the spectrum of cognitive function: Findings from the Nun Study

Riley, K. P., Snowdon, D. A., & Markesbery, W. R. (2002) · Annals of Neurology · doi:10.1002/ana.10161 · Cited by 392 · see citing works

The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bɛ at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase

Woods, Y. L., Cohen, P., Becker, W. B., Jakes, R., Goedert, M., Wang, X., & Proud, C. G. (2001) · Biochemical Journal · doi:10.1042/bj3550609 · Cited by 343 · see citing works

Brain Levels of Microtubule‐Associated Protein τ Are Elevated in Alzheimer's Disease: A Radioimmuno‐Slot‐Blot Assay for Nanograms of the Protein

Khatoon, S., Grundke, I., & Iqbal, K. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb09432.x · Cited by 304 · see citing works

Untitled work

(1993) · PubMed · Cited by 301 · see citing works

Population-based study of the prevalence and presentation of dementia in adults with Down's syndrome

Holland, A. J., Hon, J., Huppert, F. A., Stevens, F., & Watson, P. (1998) · The British Journal of Psychiatry · doi:10.1192/bjp.172.6.493 · Cited by 288 · see citing works

DYRK1A-mediated Hyperphosphorylation of Tau

Ryoo, S., Jeong, H. K., Radnaabazar, C., Yoo, J.-J., Cho, H.-J., Lee, H. W., Kim, I.-S., Cheon, Y. H., Ahn, Y. S., Chung, S., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m707358200 · Cited by 285 · see citing works

Sequence Characteristics, Subcellular Localization, and Substrate Specificity of DYRK-related Kinases, a Novel Family of Dual Specificity Protein Kinases

Becker, W. B., Weber, Y. G., Wetzel, K., EIRMBTER, K., Tejedor, F. J., & Joost, H. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.40.25893 · Cited by 285 · see citing works

Microtubule-Associated Protein Tau

Yen, S.-H. C., Nacharaju, P., Ko, L., Kenessey, Á., & Liu, W.-K. (1998) · Elsevier eBooks · doi:10.1016/b978-012734610-6/50012-9 · Cited by 284 · see citing works

The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between β-amyloid production and tau phosphorylation in Alzheimer disease

Kimura, R., Kamino, K., Yamamoto, M., Nuripa, A., Kida, T., Kazui, H., Hashimoto, R., Tanaka, T., Kudo, T., Yamagata, H., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddl437 · Cited by 281 · see citing works

Glycogen Synthase Kinase 3β Phosphorylates Tau at Both Primed and Unprimed Sites

Cho, J.-H., & Johnson, G. V. W. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m206236200 · Cited by 266 · see citing works

Specificity Determinants of Substrate Recognition by the Protein Kinase DYRK1A

Himpel, S., Tegge, W. J., Frank, R., Leder, S., Joost, H., & Becker, W. B. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.4.2431 · Cited by 235 · see citing works

τ in Paired Helical Filaments Is Functionally Distinct from Fetal τ: Assembly Incompetence of Paired Helical Filament‐τ

Yoshida, H., & Ihara, Y. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb03642.x · Cited by 232 · see citing works

Dual‐specificity tyrosine(Y)‐phosphorylation regulated kinase 1A‐mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer’s disease

Ryoo, S., Cho, H., Lee, H. W., Jeong, H. K., Radnaabazar, C., Kim, Y., Kim, M., Son, M., Seo, H., Chung, S., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05075.x · Cited by 227 · see citing works

DYRK1A BAC transgenic mice show altered synaptic plasticity with learning and memory defects

Ahn, K.-J., Jeong, H. K., Choi, H.-S., Ryoo, S.-R., Kim, Y. J., Goo, J.-S., Choi, S.-Y., Han, J.-S., Ha, I., & Song, W.-J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.12.006 · Cited by 220 · see citing works

A human homologue of Drosophila minibrain (MNB) is expressed in the neuronal regions affected in Down syndrome and maps to the critical region

Guimerá, J. (1996) · Human Molecular Genetics · doi:10.1093/hmg/5.9.1305 · Cited by 217 · see citing works

Site-specific effects of tau phosphorylation on its microtubule assembly activity and self-aggregation

Liu, F., Li, B., Tung, E., Grundke‐Iqbal, I., Iqbal, K., & Gong, C. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05955.x · Cited by 208 · see citing works

Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with down syndrome

Dowjat, W. K., Adayev, T., Kuchna, I., Nowicki, K., Palminiello, S., Hwang, Y. W., & Wegiel, J. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2006.11.026 · Cited by 190 · see citing works

Tau Becomes a More Favorable Substrate for GSK-3 When It Is Prephosphorylated by PKA in Rat Brain

Liu, S. J., Zhang, J. Y., Li, H. L., Fang, Z., Wang, Q., Deng, H. M., Gong, C. X., Grundke, I., Iqbal, K., & Wang, J. Z. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406109200 · Cited by 186 · see citing works

HumanMinibrainHomologue (MNBH/DYRK1): Characterization, Alternative Splicing, Differential Tissue Expression, and Overexpression in Down Syndrome

Guimera, J., Casas, C., Estivill, X., & Pritchard, M. (1999) · Genomics · doi:10.1006/geno.1999.5775 · Cited by 186 · see citing works

Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models

Ferrer, I., Barrachina, M., Puig, B., de Lagrán, M. M., Martı́, E., Ávila, J., & Dierssen, M. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.03.020 · Cited by 181 · see citing works

Isolation of Human and Murine Homologues of theDrosophilaMinibrain Gene: Human Homologue Maps to 21q22.2 in the Down Syndrome “Critical Region”

Song, W., Sternberg, L. R., Kasten-Sportès, C., Keuren, M. L. V., Chung, S.-H., Slack, A. C., Miller, D. E., Glover, T. W., Chiang, P.-W., Lou, L., et al. (1996) · Genomics · doi:10.1006/geno.1996.0636 · Cited by 177 · see citing works

Casein Kinase 1 Delta Phosphorylates Tau and Disrupts Its Binding to Microtubules

Li, G., Yin, H., & Kuret, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m314116200 · Cited by 159 · see citing works

A Chromosome 21 Critical Region Does Not Cause Specific Down Syndrome Phenotypes

Olson, L. E., Richtsmeier, J., Leszl, J. M., & Reeves, R. H. (2004) · Science · doi:10.1126/science.1098992 · Cited by 153 · see citing works

Truncation of CDK5 Activator p35 Induces Intensive Phosphorylation of Ser202/Thr205 of Human Tau

Hashiguchi, M., Saito, T., Hisanaga, S., & Hashiguchi, T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207426200 · Cited by 149 · see citing works

Alzheimer's Disease Abnormally Phosphorylated τ Is Dephosphorylated by Protein Phosphatase‐2B (Calcineurin)

Gong, C., Singh, T. J., Grundke, I., & Iqbal, K. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.62020803.x · Cited by 145 · see citing works

Dyrk1A expression pattern supports specific roles of this kinase in the adult central nervous system

Martı́, E., Altafaj, X., Dierssen, M., de la Luna, S., Fotaki, V., Alvarez, M., Pérez-Riba, M., Ferrer, I., & Estivill, X. (2003) · Brain Research · doi:10.1016/s0006-8993(02)04069-6 · Cited by 136 · see citing works

Mitochondrial dysfunction and tau hyperphosphorylation in Ts1Cje, a mouse model for Down syndrome

Ebrahim, A. S., Shimohata, A., Akagi, T., Yu, W., Yamaguchi, M., Murayama, M., Chui, D., Takeuchi, T., Amano, K., Subramhanya, K. H., et al. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl211 · Cited by 118 · see citing works

Dyrk1A Phosphorylates α-Synuclein and Enhances Intracellular Inclusion Formation

Kim, E. J., Sung, J. Y., Lee, H. J., Rhim, H., Hasegawa, M., Iwatsubo, T., Min, D. S., Kim, J., Paik, S. R., & Chung, K. C. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606147200 · Cited by 113 · see citing works

Phosphorylation of tau protein by recombinant GSK‐3β: pronounced phosphorylation at select Ser/Thr‐Pro motifs but no phosphorylation at Ser262 in the repeat domain

Godemann, R., Biernat, J., Mandelkow, E., & Mandelkow�, E. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00741-3 · Cited by 110 · see citing works

The protein kinase DYRK1A phosphorylates the splicing factor SF3b1/SAP155 at Thr434, a novel in vivo phosphorylation site

de Graaf, K., Czajkowska, H., Rottmann, S., Packman, L. C., Lilischkis, R., Lüscher, B., & Becker, W. B. (2006) · BMC Biochemistry · doi:10.1186/1471-2091-7-7 · Cited by 109 · see citing works

Aberrant glycosylation modulates phosphorylation of tau by protein kinase A and dephosphorylation of tau by protein phosphatase 2A and 5

Liu, F., Zaidi, T., Iqbal, K., Grundke, I., & Gong, C. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00510-9 · Cited by 106 · see citing works

Dynamic Regulation of Expression and Phosphorylation of Tau by Fibroblast Growth Factor-2 In Neural Progenitor Cells from Adult Rat Hippocampus

Tatebayashi, Y., Iqbal, K., & Grundke, I. (1999) · Journal of Neuroscience · doi:10.1523/jneurosci.19-13-05245.1999 · Cited by 106 · see citing works

Dynamin is a minibrain kinase/dual specificity Yak1-related kinase 1A substrate

Chen-Hwang, M.-C., Chen, H.-R., Elzinga, M., & Hwang, Y.-W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111101200 · Cited by 106 · see citing works

Multiple roles of the DSCR1 (Adapt78 or RCAN1) gene and its protein product Calcipressin 1 (or RCAN1) in disease

Harris, C. D., Ermak, G., & Davies, K. J. A. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5085-4 · Cited by 105 · see citing works

Formation of aberrant phosphotau fibrillar polymers in neural cultured cells

Pérez, M., Hernández, F., Gómez‐Ramos, A., Smith, M. A., Perry, G. L., & Ávila, J. (2002) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2002.02794.x · Cited by 103 · see citing works

Expression patterns and subcellular localization of the Down syndrome candidate protein MNB/DYRK1A suggest a role in late neuronal differentiation

Hämmerle, B., Carnicero, A., Elizalde, C., Cerón, J., Martı́nez, S., & Tejedor, F. J. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02665.x · Cited by 103 · see citing works

Reconstitution of Neuronal Cdc2-like Kinase from Bacteria-expressed Cdk5 and an Active Fragment of the Brain-specific Activator

Qi, R. Z., Huang, Q., Lee, K., Lew, J., & Wang, J. H.-C. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.18.10847 · Cited by 99 · see citing works

GSK-3 inhibitors for Alzheimer’s disease

Ávila, J., & Hernández, F. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.11.1527 · Cited by 96 · see citing works

Cell type- and brain structure-specific patterns of distribution of minibrain kinase in human brain

Węgiel, J., Kuchna, I., Nowicki, K., Frackowiak, J., Dowjat, K., Silverman, W. P., Reisberg, ‌., de Leon, M. J., Wısnıewskı, T., Adayev, T., et al. (2004) · Brain Research · doi:10.1016/j.brainres.2004.03.008 · Cited by 80 · see citing works

Dysregulation of Protein Phosphorylation/Dephosphorylation in Alzheimer′s Disease: A Therapeutic Target

Gong, C., Liu, F., Grundke, I., & Iqbal, K. (2006) · BioMed Research International · doi:10.1155/jbb/2006/31825 · Cited by 79 · see citing works

Phosphorylation of Amphiphysin I by Minibrain Kinase/Dual-specificity Tyrosine Phosphorylation-regulated Kinase, a Kinase Implicated in Down Syndrome

Murakami, N., Xie, W. Q., Lu, R. C., Chen‐Hwang, M., Wieraszko, A., & Hwang, Y. W. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513497200 · Cited by 70 · see citing works

Dyrk1A overexpression in immortalized hippocampal cells produces the neuropathological features of down syndrome

Park, J., Yang, E. J., Yoon, J. H., & Chung, K. C. (2007) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2007.07.007 · Cited by 61 · see citing works

Casein kinase-1 isoforms differentially associate with neurofibrillary and granulovacuolar degeneration lesions

Kannanayakal, T. J., Tao, H., Vandré, D. D., & Kuret, J. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0049-9 · Cited by 59 · see citing works

RCAN1 (DSCR1 or Adapt78)* stimulates expression of GSK‐3β

Ermak, G., Harris, C. D., Battocchio, D., & Davies, K. J. A. (2006) · FEBS Journal · doi:10.1111/j.1742-4658.2006.05217.x · Cited by 58 · see citing works

Mnb/Dyrk1A Phosphorylation Regulates the Interaction of Dynamin 1 with SH3 Domain-Containing Proteins

Huang, Y. Q., Chen‐Hwang, M., Dolios, G., Murakami, N., Padovan, J. C., Wang, R., & Hwang, Y. (2004) · Biochemistry · doi:10.1021/bi036060+ · Cited by 51 · see citing works

Casein kinase 1 alpha associates with the tau-bearing lesions of inclusion body myositis

Kannanayakal, T. J., Mendell, J. R., & Kuret, J. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2007.11.066 · Cited by 22 · see citing works

Alzheimer's disease

Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336 · see citing works

Down syndrome

Antonarakis, S. E., Skotko, B. G., Rafii, M. S., Strydom, A., Pape, S. E., Bianchi, D. W., Sherman, S. L., & Reeves, R. H. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0143-7 · Cited by 964 · see citing works

Tau and neurodegenerative disease: the story so far

Iqbal, K., Liu, F., & Gong, C.-X. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.225 · Cited by 806 · see citing works

Mechanisms of tau-induced neurodegeneration

Iqbal, K., Liu, F., Gong, C.-X., Alonso, A. D. C., & Grundke-Iqbal, I. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0486-3 · Cited by 628 · see citing works

A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome

Wiseman, F. K., Al-Janabi, T., Hardy, J., Karmiloff-Smith, A., Nizetic, D., Tybulewicz, V. L. J., Fisher, E. M. C., & Strydom, A. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3983 · Cited by 562 · see citing works

Tau Protein Modifications and Interactions: Their Role in Function and Dysfunction

Mietelska‐Porowska, A., Wasik, U., Goras, M., Filipek, A., & Niewiadomska, G. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15034671 · Cited by 407 · see citing works

Dementia in Down syndrome: unique insights for Alzheimer disease research

Lott, I. T., & Head, E. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0132-6 · Cited by 383 · see citing works

Personality and risk of Alzheimer's disease: New data and meta‐analysis

Terracciano, A., Sutin, A. R., An, Y., O’Brien, R., Ferrucci, L., Zonderman, A. B., & Resnick, S. M. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.03.002 · Cited by 331 · see citing works

Down syndrome and Alzheimer's disease: common pathways, common goals

Hartley, D., Blumenthal, T., Carrillo, M., DiPaolo, G., Esralew, L., Gardiner, K., Granholm, A.-C., Iqbal, K., Krams, M., Lemere, C., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.10.007 · Cited by 290 · see citing works

The role of DYRK1A in neurodegenerative diseases

Węgiel, J., Gong, C., & Hwang, Y. (2010) · FEBS Journal · doi:10.1111/j.1742-4658.2010.07955.x · Cited by 288 · see citing works

Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation

Göckler, N., Jofré, G., Papadopoulos, C., Soppa, U., Tejedor, F., & Becker, W. (2009) · The FEBS Journal · doi:10.1111/j.1742-4658.2009.07346.x · Cited by 266 · see citing works

Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A

Ogawa, Y., Nonaka, Y., Goto, T., Ohnishi, E., Hiramatsu, T., Kii, I., Yoshida, M., Ikura, T., Onogi, H., Shibuyà, H., et al. (2010) · Nature Communications · doi:10.1038/ncomms1090 · Cited by 276 · see citing works

Down syndrome--recent progress and future prospects

Wiseman, F. K., Alford, K. A., Tybulewicz, V. L. J., & Fisher, E. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp010 · Cited by 247 · see citing works

Dysregulation of Insulin Signaling, Glucose Transporters, O-GlcNAcylation, and Phosphorylation of Tau and Neurofilaments in the Brain

Deng, Y., Li, B., Liu, Y. M., Iqbal, K., Grundke, I., & Gong, C. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.090157 · Cited by 233 · see citing works

Phosphorylation of tau at Thr212, Thr231, and Ser262 combined causes neurodegeneration

Alonso, A. D., Di Clerico, J., Li, B., Corbo, C. P., Alaniz, M. E., Grundke-Iqbal, I., & Iqbal, K. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.110957 · Cited by 236 · see citing works

MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders

Maes, O. C., Chertkow, H. M., Wang, E., & Schipper, H. M. (2009) · Current Genomics · doi:10.2174/138920209788185252 · Cited by 217 · see citing works

It’s all about tau

Tapia‐Rojas, C., Cabezas-Opazo, F., Deaton, C. A., Vergara, E. H., Johnson, G. V. W., & Quintanilla, R. A. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.005 · Cited by 195 · see citing works

DYRK1A, a dosage-sensitive gene involved in neurodevelopmental disorders, is a target for drug development in down syndrome

Duchon, A., & Herault, Y. (2016) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2016.00104 · Cited by 181 · see citing works

Increased Dosage of Dyrk1A Alters Alternative Splicing Factor (ASF)-regulated Alternative Splicing of Tau in Down Syndrome

Shi, J., Zhang, T., Zhou, C., Chohan, M. O., Gu, X., Węgiel, J., Zhou, J., Hwang, Y., Iqbal, K., Grundke, I., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802645200 · Cited by 179 · see citing works

Developmental regulation of tau phosphorylation, tau kinases, and tau phosphatases

Yu, Y., Run, X., Liang, Z., Li, Y., Liu, F., Liu, Y. M., Iqbal, K., Grundke, I., & Gong, C. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.05882.x · Cited by 177 · see citing works

DYRK1A and cognition: A lifelong relationship

Arbonés, M. L., Thomazeau, A., Nakano-Kobayashi, A., Hagiwara, M., & Delabar, J. M. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.09.010 · Cited by 165 · see citing works

Tau and Tauopathies

Lee, G. S., & Leugers, C. J. (2012) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-385883-2.00004-7 · Cited by 166 · see citing works

Type 2 Diabetes Mellitus and Alzheimer’s Disease: Shared Molecular Mechanisms and Potential Common Therapeutic Targets

Hamzé, R., Delangre, E., Tolu, S., Moreau, M., Janel, N., Bailbé, D., & Movassat, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315287 · Cited by 163 · see citing works

Structures of Down Syndrome Kinases, DYRKs, Reveal Mechanisms of Kinase Activation and Substrate Recognition

Soundararajan, M., Roos, A. K., Savitsky, P. A., Filippakopoulos, P., Kettenbach, A. N., Olsen, J. V., Gerber, S. A., Eswaran, J., Knapp, S., & Elkins, J. M. (2013) · Structure · doi:10.1016/j.str.2013.03.012 · Cited by 160 · see citing works

Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain

Perluigi, M., Pupo, G., Tramutola, A., Cini, C., Coccia, R., Barone, E., Head, E., Butterfield, D. A., & Di Domenico, F. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.04.007 · Cited by 155 · see citing works

DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications

Abbassi, R. H., Johns, T. G., Kassiou, M., & Munoz, L. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.03.004 · Cited by 156 · see citing works

Does modulation of tau hyperphosphorylation represent a reasonable therapeutic strategy for Alzheimer’s disease? From preclinical studies to the clinical trials

Basheer, N., Smolek, T., Hassan, I., Liu, F., Iqbal, K., Zilka, N., & Novak, P. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02113-z · Cited by 159 · see citing works

Recent Advances in the Design, Synthesis, and Biological Evaluation of Selective DYRK1A Inhibitors: A New Avenue for a Disease Modifying Treatment of Alzheimer’s?

Smith, B. E., Medda, F., Gokhale, V. M., Dunckley, T. L., & Hulme, C. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn300094k · Cited by 146 · see citing works

Down syndrome: searching for the genetic culprits

Lana-Elola, E., Watson-Scales, S., Fisher, E., & Tybulewicz, V. (2011) · Disease Models & Mechanisms · doi:10.1242/dmm.008078 · Cited by 149 · see citing works

Communication breaks-Down: From neurodevelopment defects to cognitive disabilities in Down syndrome

Contestabile, A., Benfenati, F., & Gasparini, L. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.01.003 · Cited by 134 · see citing works

Dyrk1 inhibition improves Alzheimer's disease‐like pathology

Branca, C., Shaw, D. M., Belfiore, R., Gokhale, V. M., Shaw, A. Y., Foley, C., Smith, B. E., Hulme, C., Dunckley, T. L., Meechoovet, B., et al. (2017) · Aging Cell · doi:10.1111/acel.12648 · Cited by 132 · see citing works

Aneuploidy: From a Physiological Mechanism of Variance to Down Syndrome

Dierssen, M., Hérault, Y., & Estivill, X. (2009) · Physiological Reviews · doi:10.1152/physrev.00032.2007 · Cited by 132 · see citing works

Formaldehyde induces hyperphosphorylation and polymerization of Tau protein both in vitro and in vivo

Lü, J., Jun-Ye, M. I. A. O., Su, T., Liu, Y., & He, R. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.04.028 · Cited by 132 · see citing works

Tauopathy: A common mechanism for neurodegeneration and brain aging

Saha, P., & Sen, N. (2019) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2019.01.007 · Cited by 128 · see citing works

The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome

Węgiel, J., Dowjat, K., Kaczmarski, W., Kuchna, I., Nowicki, K., Frackowiak, J., Mazur‐Kolecka, B., Wegiel, J., Silverman, W. P., Reisberg, ‌., et al. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0419-6 · Cited by 113 · see citing works

Hyperphosphorylation-Induced Tau Oligomers

Iqbal, K., Gong, C., & Liu, F. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00112 · Cited by 111 · see citing works

Truncation and activation of GSK-3β by calpain I: a molecular mechanism links to tau hyperphosphorylation in Alzheimer's disease

Jin, N., Yin, X., Yu, D., Cao, M., Gong, C., Iqbal, K., Ding, F., Gu, X., & Liu, F. (2015) · Scientific Reports · doi:10.1038/srep08187 · Cited by 107 · see citing works

New Perspectives of Dyrk1A Role in Neurogenesis and Neuropathologic Features of Down Syndrome

Park, J., & Chung, K. (2013) · Experimental Neurobiology · doi:10.5607/en.2013.22.4.244 · Cited by 63 · see citing works

Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome

Tramutola, A., Lanzillotta, C., Barone, E., Arena, A., Zuliani, I., Mosca, L., Blarzino, C., Butterfield, D. A., Marzia Perluigi, A., & Domenico, F. D. (2018) · Translational Neurodegeneration · doi:10.1186/s40035-018-0133-9 · Cited by 101 · see citing works

Normalizing the gene dosage of Dyrk1A in a mouse model of down syndrome rescues several Alzheimer’s disease phenotypes

García-Cerro, S., Rueda, N., Vidal, V., Lantigua, S., & Martínez-Cué, C. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.06.010 · Cited by 100 · see citing works

Link Between DYRK1A Overexpression and Several-Fold Enhancement of Neurofibrillary Degeneration With 3-Repeat Tau Protein in Down Syndrome

Węgiel, J., Kaczmarski, W., Barua, M., Kuchna, I., Nowicki, K., Wang, K.-C., Wegiel, J., Mazur‐Kolecka, B., Frackowiak, J., Mazur‐Kolecka, B., et al. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318202bfa1 · Cited by 98 · see citing works

Dyrk1A overexpression leads to increase of 3R-tau expression and cognitive deficits in Ts65Dn down syndrome mice

Yin, X., Jin, N., Shi, J., Zhang, Y., Wu, Y., Gong, C.-X., Iqbal, K., & Liu, F. (2017) · Scientific Reports · doi:10.1038/s41598-017-00682-y · Cited by 93 · see citing works

The genomically mosaic brain: Aneuploidy and more in neural diversity and disease

Bushman, D. M., & Chun, J. J. M. (2013) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2013.02.003 · Cited by 93 · see citing works

Dual-specificity Tyrosine Phosphorylation-regulated Kinase 1A (Dyrk1A) Modulates Serine/Arginine-rich Protein 55 (SRp55)-promoted Tau Exon 10 Inclusion

Yin, X., Jin, N., Gu, J., Shi, J., Zhou, J., Gong, C., Iqbal, K., Grundke, I., & Liu, F. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.355412 · Cited by 93 · see citing works

Nonprimed and DYRK1A-primed GSK3 beta-phosphorylation sites on MAP1B regulate microtubule dynamics in growing axons.

Scales, T., Lin, S., Kraus, M., Goold, R., & Gordon-Weeks, P. (2009) · Journal of Cell Science · doi:10.1242/jcs.040162 · Cited by 4 · see citing works

Selective inhibition of the kinase DYRK1A by targeting its folding process

Kii, I., Sumida, Y., Goto, T., Sonamoto, R., Okuno, Y., Yoshida, S., Kato‐Sumida, T., Koike, Y., Abe, M., Nonaka, Y., et al. (2016) · Nature Communications · doi:10.1038/ncomms11391 · Cited by 90 · see citing works

mTOR in Down syndrome: Role in Aß and tau neuropathology and transition to Alzheimer disease-like dementia

Di Domenico, F., Tramutola, A., Foppoli, C., Head, E., Perluigi, M., & Butterfield, D. A. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.08.009 · Cited by 89 · see citing works

Neuroimaging and other modalities to assess Alzheimer's disease in Down syndrome

Neale, N., Padilla, C., Fonseca, L. M., Holland, T., & Zaman, S. H. (2017) · NeuroImage Clinical · doi:10.1016/j.nicl.2017.10.022 · Cited by 86 · see citing works

GSK-3β, FYN, and DYRK1A: Master Regulators in Neurodegenerative Pathways

Demuro, S., Martino, R. M. C. D., Ortega, J. A., & Cavalli, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22169098 · Cited by 85 · see citing works

Two key genes closely implicated with the neuropathological characteristics in Down syndrome: DYRK1A and RCAN1

Park, J., Oh, Y., & Chung, K. C. (2009) · BMB Reports · doi:10.5483/bmbrep.2009.42.1.006 · Cited by 86 · see citing works

Antioxidants in Down syndrome

Lott, I. T. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.12.010 · Cited by 82 · see citing works

Protein Phosphorylation is a Key Mechanism in Alzheimer’s Disease

Oliveira, J., Costa, M., de Almeida, M. S. C., Silva, O. A. B. D. C. E., & Henriques, A. G. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170176 · Cited by 68 · see citing works

Dyrk1A Inhibition as Potential Treatment for Alzheimer’S Disease

Stotani, S., Giordanetto, F., & Medda, F. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0013 · Cited by 78 · see citing works

The down syndrome candidate dual-specificity tyrosine phosphorylation-regulated kinase 1A phosphorylates the neurodegeneration-related septin 4

Sitz, J. H., Baumgärtel, K., Hämmerle, B., Papadopoulos, C., Hekerman, P., Tejedor, F. J., Becker, W. B., & Lutz, B. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.09.034 · Cited by 79 · see citing works

Dyrk1a from gene function in development and physiology to dosage correction across life span in down syndrome

Atas-Ozcan, H., Brault, V., Duchon, A., & Herault, Y. (2021) · Genes · doi:10.3390/genes12111833 · Cited by 78 · see citing works

The DREAM complex functions as conserved master regulator of somatic DNA-repair capacities

Bujarrabal-Dueso, A., Sendtner, G., Meyer, D. H., Chatzinikolaou, G., Stratigi, K., Garinis, G. A., & Schumacher, B. (2023) · Nature Structural & Molecular Biology · doi:10.1038/s41594-023-00942-8 · Cited by 78 · see citing works

Autism-associated Dyrk1a truncation mutants impair neuronal dendritic and spine growth and interfere with postnatal cortical development

Dang, T., Duan, W. Y., Yu, B., Tong, D. L., Cheng, C., Zhang, Y. F., Wu, W., Ye, K., Zhang, W. X., Wu, M., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.253 · Cited by 76 · see citing works

Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25–35 peptide administration in mice

Naert, G., Ferré, V. M., Meunier, J., Keller, E., Malmström, S., Givalois, L., Carreaux, F., Bazureau, J. P., & Maurice, T. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.03.018 · Cited by 75 · see citing works

Development of DANDYs, New 3,5-Diaryl-7-azaindoles Demonstrating Potent DYRK1A Kinase Inhibitory Activity

Gourdain, S., Dairou, J., Denhez, C., Bui, L. C., Rodrigues‐Lima, F., Janel, N., Delabar, J. M., Cariou, K., & Dodd, R. H. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401049v · Cited by 74 · see citing works

Prenatal neurogenesis induction therapy normalizes brain structure and function in Down syndrome mice

Nakano-Kobayashi, A., Awaya, T., Kii, I., Sumida, Y., Okuno, Y., Yoshida, S., Sumida, T., Inoue, H., Hosoya, T., & Hagiwara, M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704143114 · Cited by 71 · see citing works

Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease

Melchior, B., Mittapalli, G. K., Lai, C., Duong‐Polk, K., Stewart, J., Güner, B., Hofilena, B. J., Tjitro, A., Anderson, S., Herman, D. S., et al. (2019) · Aging Cell · doi:10.1111/acel.13000 · Cited by 73 · see citing works

Advances in Therapeutics for Neurodegenerative Tauopathies: Moving toward the Specific Targeting of the Most Toxic Tau Species

Gerson, J. E., Castillo‐Carranza, D. L., & Kayed, R. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500143n · Cited by 73 · see citing works

Truncation and Activation of Dual Specificity Tyrosine Phosphorylation-regulated Kinase 1A by Calpain I

Jin, N., Yin, X., Gu, J., Zhang, X., Shi, J., Qian, W., Ji, Y., Cao, M., Gu, X., Ding, F., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.645507 · Cited by 71 · see citing works

Protection by sigma-1 receptor agonists is synergic with donepezil, but not with memantine, in a mouse model of amyloid-induced memory impairments

Maurice, T. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.09.020 · Cited by 66 · see citing works

Tau phosphorylation and neuronal apoptosis induced by the blockade of PP2A preferentially involve GSK3β

Martin, L., Page, G., & Terro, F. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.05.010 · Cited by 65 · see citing works

Design and Synthesis of a Library of Lead-Like 2,4-Bisheterocyclic Substituted Thiophenes as Selective Dyrk/Clk Inhibitors

Schmitt, C., Kail, D., Mariano, M., Empting, M., Weber, N., Paul, T., Hartmann, R. W., & Engel, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087851 · Cited by 64 · see citing works

Role of Tau Protein in Neuronal Damage in Alzheimer's Disease and Down Syndrome

Cárdenas, A. M., Ardiles, Á. O., Barraza, N., Báez‐Matus, X., & Caviedes, P. A. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.10.012 · Cited by 63 · see citing works

Tau Phosphorylation and Aggregation in the Developing Human Brain

Hefti, M. M., Kim, S., Bell, A. J., Betters, R. K., Fiock, K. L., Iida, M. A., Smalley, M. E., Farrell, K. W., Fowkes, M. E., & Crary, J. F. (2019) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlz073 · Cited by 63 · see citing works

Structural based study to identify new potential inhibitors for dual specificity tyrosine-phosphorylation- regulated kinase

Bhardwaj, V. K., SINGH, R. K., Sharma, J., Das, P., & Purohit, R. (2020) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2020.105494 · Cited by 61 · see citing works

Epigenetics: The neglected key to minimize learning and memory deficits in Down syndrome

Dekker, A. D., Deyn, P. P. D., & Rots, M. G. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.05.004 · Cited by 62 · see citing works

Regulation of alternative splicing of tau exon 10 by 9G8 and Dyrk1A

Ding, S., Shi, J., Qian, W., Iqbal, K., Grundke, I., Gong, C., & Liu, F. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.11.021 · Cited by 60 · see citing works

Alzheimer's disease neurofibrillary degeneration: pivotal and multifactorial

Iqbal, K., Wang, X., Blanchard, J., Liu, F., Gong, C., & Grundke, I. (2010) · Biochemical Society Transactions · doi:10.1042/bst0380962 · Cited by 61 · see citing works

Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes

Stringer, M., Abeysekera, I., Thomas, J. R., LaCombe, J., Stancombe, K., Stewart, R. B., Dria, K. J., Wallace, J. M., Goodlett, C. R., & Roper, R. J. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.05.003 · Cited by 59 · see citing works

Tangles, Toxicity, and Tau Secretion in AD – New Approaches to a Vexing Problem

Gendreau, K. L., & Hall, G. F. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00160 · Cited by 60 · see citing works

DYRK1A binds to an evolutionarily conserved WD40-repeat protein WDR68 and induces its nuclear translocation

Miyata, Y., & Nishida, E. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.06.023 · Cited by 60 · see citing works

Nuclear import of the DSCAM‐cytoplasmic domain drives signaling capable of inhibiting synapse formation

Sachse, S., Lievens, S., Ribeiro, L. F., Dascenco, D., Masschaele, D., Horré, K., Misbaer, A., Vanderroost, N., de Smet, A.-S., Salta, E., et al. (2019) · The EMBO Journal · doi:10.15252/embj.201899669 · Cited by 60 · see citing works

Silmitasertib (CX-4945), a Clinically Used CK2-Kinase Inhibitor with Additional Effects on GSK3β and DYRK1A Kinases: A Structural Perspective

Grygier, P., Pustelny, K., Nowak, J., Golik, P., Popowicz, G. M., Plettenburg, O., Dubin, G., Menezes, F., & Czarna, A. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01887 · Cited by 58 · see citing works

Altered regulation of tau phosphorylation in a mouse model of down syndrome aging

Sheppard, O., Plattner, F., Rubin, A. N., Slender, A., Linehan, J. M., Brandner, S., Tybulewicz, V. L. J., Fisher, E., & Wiseman, F. K. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.06.025 · Cited by 57 · see citing works

Engineering DYRK1A overdosage yields Down syndrome-characteristic cortical splicing aberrations

Toiber, D., Azkona, G., Ben‐Ari, S., Torán, N., Soreq, H., & Dierssen, M. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.06.011 · Cited by 55 · see citing works

Inhibition of DYRK1A proteolysis modifies its kinase specificity and rescues Alzheimer phenotype in APP/PS1 mice

Souchet, B., Audrain, M., Billard, J. M., Dairou, J., Fol, R. R., Orefice, N. S., Tada, S., Gu, Y., Dufayet‐Chaffaud, G., Limanton, E., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0678-6 · Cited by 55 · see citing works

Impact of increased <i>APP</i> gene dose in Down syndrome and the Dp16 mouse model

Sawa, M., Overk, C., Becker, A., Derse, D., Albay, R., Weldy, K., Salehi, A., Beach, T. G., Doran, E., Head, E., et al. (2022) · Alzheimer's &amp; Dementia · doi:10.1002/alz.12463 · Cited by 54 · see citing works

Neurogenetic disorders across the lifespan: from aberrant development to degeneration

Hickman, R. A., O’Shea, S. A., Mehler, M. F., & Chung, W. K. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-021-00595-5 · Cited by 55 · see citing works

Plasma p-tau212 antemortem diagnostic performance and prediction of autopsy verification of Alzheimer’s disease neuropathology

Kac, P. R., González‐Ortiz, F., Emeršič, A., Dulewicz, M., Koutarapu, S., Turton, M., An, Y., Smirnov, D. S., Kulczyńska‐Przybik, A., Varma, V. R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46876-7 · Cited by 51 · see citing works

Probable Participation of 14-3-3 in Tau Protein Oligomerization and Aggregation

Sluchanko, N. N., & Gusev, N. B. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110692 · Cited by 51 · see citing works

Therapeutics potentiating microglial p21-Nrf2 axis can rescue neurodegeneration caused by neuroinflammation

Nakano-Kobayashi, A., Fukumoto, A., Morizane, A., Nguyen, D. T., Le, T. M., Hashida, K., Hosoya, T., Takahashi, R., Takahashi, J. B., Hori, O., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc1428 · Cited by 50 · see citing works

Frontal cortex and striatal cellular and molecular pathobiology in individuals with Down syndrome with and without dementia

Perez, S. E., Miguel, J. C., He, B., Malek‐Ahmadi, M. H., Abrahamson, E. E., Ikonomović, M. D., Lott, I. T., Doran, E. W., Alldred, M. J., Ginsberg, S. D., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-01965-6 · Cited by 47 · see citing works

Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors

Czarna, A., Wang, J., Zelencova-Gopejenko, D., Liu, Y., Deng, X., Choi, H. G., Zhang, T., Zhou, W., Chang, J. W., Kildalsen, H., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01847 · Cited by 48 · see citing works

The Molecular Chaperone TRiC/CCT Binds to the Trp-Asp 40 (WD40) Repeat Protein WDR68 and Promotes Its Folding, Protein Kinase DYRK1A Binding, and Nuclear Accumulation

Miyata, Y., Shibata, T., Aoshima, M., Tsubata, T., & Nishida, E. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.586115 · Cited by 47 · see citing works

Targeting trisomic treatments: optimizing Dyrk1a inhibition to improve Down syndrome deficits

Stringer, M., Goodlett, C. R., & Roper, R. J. (2017) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.334 · Cited by 44 · see citing works

QSAR analysis of pyrazolidine-3,5-diones derivatives as Dyrk1A inhibitors

Koo, K. A., Kim, N. D., Chon, Y. S., Jung, M., Lee, B., Kim, J. H., & Song, W. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.02.062 · Cited by 46 · see citing works

Genetic forms of tauopathies: inherited causes and implications of Alzheimer’s disease-like TAU pathology in primary and secondary tauopathies

Langerscheidt, F., Wied, T., Kabbani, M. A. A., van Eimeren, T., Wunderlich, G., & Zempel, H. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12314-3 · Cited by 45 · see citing works

Plasma DYRK1A as a novel risk factor for Alzheimer’s disease

Janel, N., Sarazin, M., Corlier, F. W., Corne, H., de Souza, L. C., Hamelin, L., Aka, A., Lagarde, J., Bléhaut, H., Hindie, V., et al. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.61 · Cited by 45 · see citing works

Chronic Dyrk1 Inhibition Delays the Onset of AD-Like Pathology in 3xTg-AD Mice

Velázquez, R., Meechoovet, B., Ow, A., Foley, C., Shaw, A. Y., Smith, B. E., Oddo, S., Hulme, C., & Dunckley, T. L. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01684-9 · Cited by 43 · see citing works

Evaluation of the therapeutic potential of Epigallocatechin-3-gallate (EGCG) via oral gavage in young adult down syndrome mice

Goodlett, C. R., Stringer, M., LaCombe, J., Patel, R., Wallace, J. M., & Roper, R. J. (2020) · Scientific Reports · doi:10.1038/s41598-020-67133-z · Cited by 43 · see citing works

RNA editing of microtubule-associated protein tau circular RNAs promotes their translation and tau tangle formation

Welden, J. R., Margvelani, G., Maquera, K. A. A., Gudlavalleti, B., Sardón, S. C. M., Campos, A. R., Robil, N., Lee, D. C., Hernandez, A. G., Wang, W., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac1129 · Cited by 42 · see citing works

Dissecting Alzheimer disease in Down syndrome using mouse models

Choong, X. Y., Tosh, J., Pulford, L. J., & Fisher, E. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00268 · Cited by 40 · see citing works

REST Regulates DYRK1A Transcription in a Negative Feedback Loop

Lü, M., Zheng, L., Han, B., Wang, L., Wang, P., Liu, H., & Sun, X. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.174540 · Cited by 39 · see citing works

The structure of a dual-specificity tyrosine phosphorylation-regulated kinase 1A–PKC412 complex reveals disulfide-bridge formation with the anomalous catalytic loop HRD(HCD) cysteine

Alexeeva, M., Åberg, E., Engh, R. A., & Rothweiler, U. (2015) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s1399004715005106 · Cited by 38 · see citing works

Modeling Down syndrome in animals from the early stage to the 4.0 models and next

Moreno, M. D. M. M., Brault, V., Birling, M., Pavlovic, G., & Hérault, Y. (2020) · Progress in brain research · doi:10.1016/bs.pbr.2019.08.001 · Cited by 32 · see citing works

The novel DYRK1A inhibitor KVN93 regulates cognitive function, amyloid-beta pathology, and neuroinflammation

Lee, H., Woo, H., Lee, H.-E., Jeon, H., Ryu, K., Nam, J. H., Jeon, S. G., Park, H., Lee, J.-S., Han, K., et al. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.08.030 · Cited by 38 · see citing works

The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome

Węgiel, J., Dowjat, K., Kaczmarski, W., Kuchna, I., Nowicki, K., Frackowiak, J., Mazur‐Kolecka, B., Wegiel, J., Silverman, W. P., Reisberg, ‌., et al. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0419-6 · Cited by 113 · see citing works

Link Between DYRK1A Overexpression and Several-Fold Enhancement of Neurofibrillary Degeneration With 3-Repeat Tau Protein in Down Syndrome

Węgiel, J., Kaczmarski, W., Barua, M., Kuchna, I., Nowicki, K., Wang, K.-C., Wegiel, J., Mazur‐Kolecka, B., Frackowiak, J., Mazur‐Kolecka, B., et al. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318202bfa1 · Cited by 98 · see citing works

The role of DYRK1A in neurodegenerative diseases

Węgiel, J., Gong, C., & Hwang, Y. (2010) · FEBS Journal · doi:10.1111/j.1742-4658.2010.07955.x · Cited by 288 · see citing works

DYRK1A-mediated Hyperphosphorylation of Tau

Ryoo, S., Jeong, H. K., Radnaabazar, C., Yoo, J.-J., Cho, H.-J., Lee, H. W., Kim, I.-S., Cheon, Y. H., Ahn, Y. S., Chung, S., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m707358200 · Cited by 285 · see citing works

Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models

Ferrer, I., Barrachina, M., Puig, B., de Lagrán, M. M., Martı́, E., Ávila, J., & Dierssen, M. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.03.020 · Cited by 181 · see citing works